EC Pharmacology And Toxicology

Case Report Volume 5 Issue 1 - 2017

Acute Myelopathy Differential Diagnosis: A Case Report

Tahir Chaudhry1*, Alice Jiang1, Janki Shah1, Andrew Rudin2, Kaiyu Ma3, Malloy Nair4 and Zoltan Fekete3

1Orange Regional Medical Center, Middletown, NY, USA
2Emergency Medicine, Orange Regional Medical Center, Middletown, NY, USA
3Neurology, Crystal Run Healthcare, Middletown, NY, USA
44Infectious Diseases, Crystal Run Healthcare, Middletown, NY, USA
*Corresponding Author: Earnest Oghenesuvwe Erhirhie, Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Chukwuemeka Odumegwu Ojukwu University, Igbariam, Nigeria.
Received: October 18, 2017; Published: November 08, 2017



A 57 year-old male patient presented to the ED with a chief complaint of paralysis and sensory deficits in his lower extremities. Preliminary diagnosis of transverse myelitis was soon ruled out. Differential diagnoses of Guillain-Barré syndrome, Lyme disease and West Nile virus were additionally ruled out. Upon closer analysis of the patient’s medication history and bloodwork analysis, vi- tamin B12 deficiency-induced myelitis and metronidazole-induced neuropathy were suspected. Upon drug cessation and cobalamin supplementation, the patient rapidly regained his ability to walk within two weeks. Due to this patient’s co-presentation of B12 defi- ciency with chronic metronidazole use and due to his rapid recovery time, this is a non-classical case that warrants further analysis.

Keywords: Metronidazole; B12; Cobalamin; Acute Myelitis; Transverse Myelitis; Paraplegia

  1. Schrier Stanley L. “Clinical Manifestations and Diagnosis of Vitamin B12 and Folate Deficiency”. Up to Date.
  2. “Zur Kenntis der perniciosen Anemie”. Verhandlungen des Deutschen Kongress fur innere Medizin 6 (1889): 84-96.
  3. Kumar N., et al. “Copper Deficiency Myelopathy Produces a Clinical Picture Like Subacute Combined Degeneration”. Neurology1 (2004): 33-39.
  4. Agamanolis Dimitri P. Nutritional CNS Disorders. Deficiency of the lipid-soluble vitamin E occurs in cases of intestinal malabsorption such as cystic fibrosis, congenital biliary atresia, intestinal resection, and abetalipoproteinemia (Bassen-Kornzweig syndrome) (2014).
  5. Hitender Kumar., et al. “Rapid onset peripheral neuropathy: A rare complication of metronidazole”. Journal of Indian Academy of Clinical Medicine4 (2012): 346-348.
  6. Johnson Melissa. “Metronidazole: an Overview”. Up to Date, Wolters Kluwer.
  7. Carroll MW., et al. “Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis”. Antimicrobial Agents and Chemotherapy8 (2013): 3903-3909.
  8. Stabler SP. “Vitamin B12 deficiency”. The New England Journal of Medicine2 (2013): 149-160.
  9. Lindenbaum J., et al. “Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or microcytosis”. The New England Journal of Medicine26 (1988): 1720-1728.
  10. Healton EB., et al. “Neurologic aspects of cobalamin deficiency”. Medicine4 (1991): 229-245.
  11. Briani Chiara., et al. “Cobalamin Deficiency: Clinical Picture and Radiological Findings”. Nutrients11 (2013): 4521-4539.
  12. Durand C., et al. “[Psychiatric Manifestations of Vitamin B12 Deficiency: a Case Report]”. L’Encephale6 (2003): 560-565.
  13. “Patterns of Abnormal Hyperintense Signal of the Spinal | Open-i”. U.S. National Library of Medicine, National Institutes of Health.
  14. Schrier Stanley L. “Diagnosis and Treatment of Vitamin B12 and Folate Deficiency”. Up To Date (2016).
  15. Kato H., et al. “[Clinical Characteristics of Metronidazole-Induced Encephalopathy: A Report of Two Cases and a Review of 32 Japanese Cases in the Literature]”. Journal of the Japanese Association for Infectious Diseases5 (2015): 559-566.
  16. Bradley WG., et al. “Metronidazole neuropathy”. British Medical Journal6087 (1977): 610-611.
  17. “Metronidazole 3D 1 w3r.Png”. Wikimedia, Fvasconcellos, (2010).
  18. “Cobalamin”. Wikimedia, NEUROtiker (2007).

Tahir Chaudhry., et al. “Acute Myelopathy Differential Diagnosis: A Case Report” ”. EC Pharmacology and Toxicology  5.1 (2017): 21-25.